Saker Advantage

The correspondence between cyclizine and morning sickness

Cyclizine is an antihistamine that has been used to treat morning sickness for many years. It is most commonly used in the first trimester of pregnancy, but can be used in the second and third trimesters as well. Cyclizine works by reducing the nausea and vomiting that can occur during pregnancy. It is also thought to help reduce the risk of developing hyperemesis gravidarum, a condition characterized by severe nausea and vomiting that can lead to dehydration and weight loss. Cyclizine is available in both pill and liquid form and is usually taken three times a day. Side effects of cyclizine include dry mouth, constipation, drowsiness, and dizziness. Read Full Report

Cyclizine and the risk of preterm labor

Cyclizine is a medication that is used to treat nausea and vomiting. It is also used to treat motion sickness. Cyclizine is in a class of medications called antihistamines. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction.

Cyclizine is also used to help treatvertigo (a condition in which you feel as though you or the things around you are spinning). Cyclizine is also sometimes used to treat irritable bowel syndrome (IBS).

Cyclizine is available under the following different brand names: Marezine, and Bonine.

Dosages of Cyclizine:

Adult and Pediatric Dosages:

Dosage Forms and Strengths

Injection

25 mg/mL

Oral Drops

2.5 mg/mL

Tablet

50 mg

Capsule

50 mg

Chewing Tablet

50 mg

More severe cases: Dosage may be increased to 100 mg every four hours

Vertigo: 25 mg to 100 mg daily in divided doses

Irritable bowel syndrome:

50 mg four times per day

Manufacturer recommends 50-100 mg/day in divided doses for up to 4 weeks

Nasal Spray

5 mg/spray (0.1 mL)

Motion Sickness

Prevention

25-50 mg one hour before departure, then 25-100 mg every four to six hours as needed during the journey

Treatment

25 mg every four to six hours as needed during the journey

Dosage Considerations – Should be Given as Follows:

Nausea and vomiting

Adult: 25 mg to 100 mg IM/IV/PO every four to six hours as needed

Pediatric: 0.6 mg/kg/dose IM/IV/PO every four hours as needed; not to exceed 4 mg/kg/day or 150 mg/day, whichever is less

Motion sickness

Adult: 25-50 mg PO one hour before departure, then 25-100 mg PO every four to six hours as needed during the journey

Pediatric: 0.5 mg/kg PO one hour before departure, then 0.1 mg/kg PO every four to six hours as needed during the journey

Irritable bowel syndrome

Adult: 50 mg PO 4 times daily for up to 4 weeks

Use: Symptomatic relief of upper gastrointestinal motility disorders

Contraindications

Obstetric paraspinal or pudendal block

Warnings/Precautions

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with cardiovascular disease, arrhythmias, hypotension, or hypertension; dizziness or fainting may occur.

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).

• Gastrointestinal obstruction/perforation: Use with caution in patients with suspected or confirmed gastrointestinal obstruction or perforation.

• Prostatic hypertrophy: Use with caution in patients with prostatic hypertrophy; may cause difficulty urinating.

• Renal impairment: Use with caution in patients with renal impairment; cyclizine is known to be substantially excreted by the kidney.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Concomitant use with other agents that cause CNS depression may potentiate the effects of cyclizine.

Special populations:

• Elderly: Use with caution in the elderly; they may be more sensitive to the effects of the drug.

• Pediatrics: Safety and efficacy have not been established in children Original source.